FDA
-
-
-
-
-
-
-
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal
-
-
-
-
-
-
-
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
-
-
-
-
-
-
-
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs
-
-
-
-
-
-
-
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) Announces Multiple Positive Business Updates
-
-
-
-
-
-
-
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
-
-
-
-
-
-
-
Akebia Therapeutics (AKBA) and U.S. Renal Care Initiate the VOICE Trial of Vafseo (vadadustat) for Patients on Dialysis
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

